Saadia Qazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Saadia Qazi has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Ariela R. Orkaby
Harvard Medical School, Boston, MA, USA
5 shared publications Christopher J. O'DOnnell
The National Heart, Lung and Blood Institute's (NHLBI) Framingham Heart Study, Framingham, MA
2 shared publications- David R. Gagnon
Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
2 shared publications Kelly Cho
Division of Aging Brigham and Women’s Hospital and Harvard Medical School Boston MA USA
2 shared publications- Luc Djoussé
VA Boston Healthcare System, 1620 Tremont Street, 3rd Floor, Boston, MA 02120, USA
2 shared publications Manas Rane
Division of Aging Brigham and Women’s Hospital and Harvard Medical School Boston MA USA
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (11)
Methadone withdrawal-associated multivessel coronary vasospasm presenting as ST-segment elevation myocardial infarction: a case report
Background: Increased catecholaminergic tone from opioid (methadone) withdrawal has been associated with cardiovascular complications, including stress-induced cardiomyopathy and possibly acute coronary syndrome. Case summary: A 75-year-old man presented with nausea, vomiting, and chills after missing 2–3 days of his daily methadone. Within 24 h, he developed acute anterior and inferior ST-segment elevation requiring emergent coronary angiography, which revealed severe multivessel vasospasm successfully treated with intracoronary nitroglycerine. Discussion: Opioid (methadone) withdrawal-induced sympathetic hyperactivation represents a biologically plausible trigger for severe epicardial coronary vasospasm and transient myocardial ischaemia, particularly in patients with underlying endothelial dysfunction or otherwise non-obstructive coronary artery disease. Early recognition of withdrawal-associated vasospastic ischaemia is critical, as prompt vasodilator therapy with nitrates and calcium-channel blockers can rapidly reverse it and prevent irreversible myocardial injury.
- 4 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (11)
Open AccessMethadone withdrawal-associated multivessel coronary vasospasm presenting as ST-segment elevation myocardial infarction: a case report
Background: Increased catecholaminergic tone from opioid (methadone) withdrawal has been associated with cardiovascular complications, including stress-induced cardiomyopathy and possibly acute coronary syndrome. Case summary: A 75-year-old man presented with nausea, vomiting, and chills after missing 2–3 days of his daily methadone. Within 24 h, he developed acute anterior and inferior ST-segment elevation requiring emergent coronary angiography, which revealed severe multivessel vasospasm successfully treated with intracoronary nitroglycerine. Discussion: Opioid (methadone) withdrawal-induced sympathetic hyperactivation represents a biologically plausible trigger for severe epicardial coronary vasospasm and transient myocardial ischaemia, particularly in patients with underlying endothelial dysfunction or otherwise non-obstructive coronary artery disease. Early recognition of withdrawal-associated vasospastic ischaemia is critical, as prompt vasodilator therapy with nitrates and calcium-channel blockers can rapidly reverse it and prevent irreversible myocardial injury.
- Open Access
- 20 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (16) , e033111
Measuring Frailty Using Self‐Report or Automated Tools to Identify Risk of Cardiovascular Events and Mortality: The Million Veteran Program
Background: Frailty, a syndrome of physiologic vulnerability, increases cardiovascular disease (CVD) risk. Whether in person or automated frailty tools are ideal for identifying CVD risk remains unclear. We calculated 3 distinct frailty scores and examined their associations with mortality and CVD events in the Million Veteran Program, a prospective cohort of nearly 1 million US veterans. Methods and Results: Veterans aged ≥50 years and enrolled from 2011 to 2018 were included. Two frailty indices (FI) based on the deficit accumulation theory were calculated: the questionnaire‐based 36‐item Million Veteran Program‐FI and 31‐item Veterans Affairs‐FI using claims data. We calculated Fried physical frailty using the self‐reported, 3‐item Study of Osteoporotic Fractures. Multivariable‐adjusted Cox models examined the association of frailty by each score with primary (all‐cause and CVD mortality) and secondary (myocardial infarction, stroke, and heart failure) outcomes. In 190 688 veterans (69±9 years, 94% male, 85% White), 33, 233 (17%) all‐cause and 10 115 (5%) CVD deaths occurred. Using Million Veteran Program‐FI, 29% were robust, 42% pre‐frail, and 29% frail. Frailty prevalence increased by age group (27% in 50‐59 to 42% in ≥90 years). Using the Million Veteran Program‐FI, over 6±2 years, frail veterans had a higher hazard of all‐cause (hazard ratio [HR], 3.05 [95% CI, 2.95–3.16]) and CVD mortality (HR, 3.65 [95% CI, 3.43–3.90]). Findings were concordant for the Veterans Affairs‐FI and Study of Osteoporotic Fractures frailty definitions, and remained significant even among younger veterans aged 50‐59 years. Conclusions: Irrespective of frailty measure, frailty is associated with a higher risk of all‐cause mortality and adverse CVD events. Further study of frailty in veterans aged <60 years old is warranted.
- 20 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (16) , e033111
Open AccessMeasuring Frailty Using Self‐Report or Automated Tools to Identify Risk of Cardiovascular Events and Mortality: The Million Veteran Program
Background: Frailty, a syndrome of physiologic vulnerability, increases cardiovascular disease (CVD) risk. Whether in person or automated frailty tools are ideal for identifying CVD risk remains unclear. We calculated 3 distinct frailty scores and examined their associations with mortality and CVD events in the Million Veteran Program, a prospective cohort of nearly 1 million US veterans. Methods and Results: Veterans aged ≥50 years and enrolled from 2011 to 2018 were included. Two frailty indices (FI) based on the deficit accumulation theory were calculated: the questionnaire‐based 36‐item Million Veteran Program‐FI and 31‐item Veterans Affairs‐FI using claims data. We calculated Fried physical frailty using the self‐reported, 3‐item Study of Osteoporotic Fractures. Multivariable‐adjusted Cox models examined the association of frailty by each score with primary (all‐cause and CVD mortality) and secondary (myocardial infarction, stroke, and heart failure) outcomes. In 190 688 veterans (69±9 years, 94% male, 85% White), 33, 233 (17%) all‐cause and 10 115 (5%) CVD deaths occurred. Using Million Veteran Program‐FI, 29% were robust, 42% pre‐frail, and 29% frail. Frailty prevalence increased by age group (27% in 50‐59 to 42% in ≥90 years). Using the Million Veteran Program‐FI, over 6±2 years, frail veterans had a higher hazard of all‐cause (hazard ratio [HR], 3.05 [95% CI, 2.95–3.16]) and CVD mortality (HR, 3.65 [95% CI, 3.43–3.90]). Findings were concordant for the Veterans Affairs‐FI and Study of Osteoporotic Fractures frailty definitions, and remained significant even among younger veterans aged 50‐59 years. Conclusions: Irrespective of frailty measure, frailty is associated with a higher risk of all‐cause mortality and adverse CVD events. Further study of frailty in veterans aged <60 years old is warranted.
- Top Cited PapersOpen Access
- 6 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (15) , e031736
Frailty and Cardiovascular Health
The incidence of frailty and cardiovascular disease (CVD) increases as the population ages. There is a bidirectional relationship between frailty and CVD, and both conditions share several risk factors and underlying biological mechanisms. Frailty has been established as an independent prognostic marker in patients with CVD. Moreover, its presence significantly influences both primary and secondary prevention strategies for adults with CVD while also posing a barrier to the inclusion of these patients in pivotal clinical trials and advanced cardiac interventions. This review discusses the current knowledge base on the relationship between frailty and CVD, how managing CVD risk factors can modify frailty, the influence of frailty on CVD management, and future directions for frailty detection and modification in patients with CVD.
- 6 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (15) , e031736
Top Cited PapersOpen AccessFrailty and Cardiovascular Health
The incidence of frailty and cardiovascular disease (CVD) increases as the population ages. There is a bidirectional relationship between frailty and CVD, and both conditions share several risk factors and underlying biological mechanisms. Frailty has been established as an independent prognostic marker in patients with CVD. Moreover, its presence significantly influences both primary and secondary prevention strategies for adults with CVD while also posing a barrier to the inclusion of these patients in pivotal clinical trials and advanced cardiac interventions. This review discusses the current knowledge base on the relationship between frailty and CVD, how managing CVD risk factors can modify frailty, the influence of frailty on CVD management, and future directions for frailty detection and modification in patients with CVD.
- Open Access
Measuring Frailty Using Self-Report or Automated Tools to Identify Risk of Cardiovascular Events and Mortality: The Million Veteran Program
Background: Frailty, a syndrome of physiologic vulnerability, increases cardiovascular disease (CVD) risk. Whether in person or automated frailty tools are ideal for identifying CVD risk remains unclear. We calculated three distinct frailty scores and examined their associations with mortality and CVD events in the Million Veteran Program (MVP). Methods: MVP is a prospective cohort of U.S. Veterans that has enrolled nearly one million Veterans. We included participants aged ≥50 years who enrolled from 2011-2018. Frailty was calculated using three tools: two frailty indices (FI) based on the accumulation of deficits theory, the 36-item MVP-FI using self-reported answers to questionaries, and the 31-item VA-FI developed using claims data. Finally, we calculated the 3-item Study of Osteoporotic Fractures Fried physical frailty score from self-report. The primary outcomes were CVD and all-cause mortality. Multivariable-adjusted Cox proportional hazards models (adjusted for age, sex, smoking, statin use, antihypertensive use, hyperlipidemia, and survey year). Secondary outcomes were myocardial infarction (MI), stroke, and heart failure (HF). Results: Among 190,688 MVP participants (mean age 69 ±9 years, 94% male, 85% white), there were 33,233 (17%) all-cause and 10,115 (5%) CVD deaths. Using MVP-FI, 29% were robust, 42% pre-frail, and 29% frail. Frailty prevalence increased by age group, from 27% in 50–59-year-olds to 42% in age≥90 years. Follow-up duration was 6±2 years. Using the MVP-FI, pre-frail and frail Veterans had a higher incidence of both all-cause mortality (pre-frail: HR=1.66, 95%CI: 1.61-1.72; frail: 3.05, 2.95-3.16) and CVD death (pre-frail: 1.76, 1.65-1.88; frail: 3.65, 3.43-3.90), as compared to robust individuals. These findings remained significant among Veterans ≥ 50 years. Findings were similar for CVD events. When frailty was measured using the VA-FI and SOF results were concordant. Conclusion: Irrespective of frailty measure used, frailty is associated with a higher risk of all-cause mortality and CVD events. Further study of frailty in individuals <60 years old is warranted.
Open AccessMeasuring Frailty Using Self-Report or Automated Tools to Identify Risk of Cardiovascular Events and Mortality: The Million Veteran Program
Background: Frailty, a syndrome of physiologic vulnerability, increases cardiovascular disease (CVD) risk. Whether in person or automated frailty tools are ideal for identifying CVD risk remains unclear. We calculated three distinct frailty scores and examined their associations with mortality and CVD events in the Million Veteran Program (MVP). Methods: MVP is a prospective cohort of U.S. Veterans that has enrolled nearly one million Veterans. We included participants aged ≥50 years who enrolled from 2011-2018. Frailty was calculated using three tools: two frailty indices (FI) based on the accumulation of deficits theory, the 36-item MVP-FI using self-reported answers to questionaries, and the 31-item VA-FI developed using claims data. Finally, we calculated the 3-item Study of Osteoporotic Fractures Fried physical frailty score from self-report. The primary outcomes were CVD and all-cause mortality. Multivariable-adjusted Cox proportional hazards models (adjusted for age, sex, smoking, statin use, antihypertensive use, hyperlipidemia, and survey year). Secondary outcomes were myocardial infarction (MI), stroke, and heart failure (HF). Results: Among 190,688 MVP participants (mean age 69 ±9 years, 94% male, 85% white), there were 33,233 (17%) all-cause and 10,115 (5%) CVD deaths. Using MVP-FI, 29% were robust, 42% pre-frail, and 29% frail. Frailty prevalence increased by age group, from 27% in 50–59-year-olds to 42% in age≥90 years. Follow-up duration was 6±2 years. Using the MVP-FI, pre-frail and frail Veterans had a higher incidence of both all-cause mortality (pre-frail: HR=1.66, 95%CI: 1.61-1.72; frail: 3.05, 2.95-3.16) and CVD death (pre-frail: 1.76, 1.65-1.88; frail: 3.65, 3.43-3.90), as compared to robust individuals. These findings remained significant among Veterans ≥ 50 years. Findings were similar for CVD events. When frailty was measured using the VA-FI and SOF results were concordant. Conclusion: Irrespective of frailty measure used, frailty is associated with a higher risk of all-cause mortality and CVD events. Further study of frailty in individuals <60 years old is warranted.
- 16 February 2023
- Published by Springer Nature in Current Cardiology Reports
- Vol. 25 (4) , 249-259
Frailty and Cardiovascular Mortality: A Narrative Review
Purpose of Review The goal of the narrative review is to provide an overview of the epidemiology of frailty in cardiovascular disease and cardiovascular mortality and discuss applications of frailty in cardiovascular care of older adults. Recent Findings Frailty is highly prevalent in older adults with cardiovascular disease and is a robust, independent predictor of cardiovascular death. There is a growing interest in using frailty to inform management of cardiovascular disease either through pre- or post-treatment prognostication or by delineating treatment heterogeneity in which frailty serves to distinguish patients with differential harms or benefits from a given therapy. Summary Frailty can enable more individualized treatment in older adults with cardiovascular disease. Future studies are needed to standardize frailty assessment across cardiovascular trials and enable implementation of frailty assessment in cardiovascular clinical practice.
- 16 February 2023
- Published by Springer Nature in Current Cardiology Reports
- Vol. 25 (4) , 249-259
Frailty and Cardiovascular Mortality: A Narrative Review
Purpose of Review The goal of the narrative review is to provide an overview of the epidemiology of frailty in cardiovascular disease and cardiovascular mortality and discuss applications of frailty in cardiovascular care of older adults. Recent Findings Frailty is highly prevalent in older adults with cardiovascular disease and is a robust, independent predictor of cardiovascular death. There is a growing interest in using frailty to inform management of cardiovascular disease either through pre- or post-treatment prognostication or by delineating treatment heterogeneity in which frailty serves to distinguish patients with differential harms or benefits from a given therapy. Summary Frailty can enable more individualized treatment in older adults with cardiovascular disease. Future studies are needed to standardize frailty assessment across cardiovascular trials and enable implementation of frailty assessment in cardiovascular clinical practice.
- Open Access
- 31 December 2022
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 26
Distribution, determinants and normal reference values of aortic arch width: Thoracic aortic geometry in the Framingham Heart Study
- 31 December 2022
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 26
Open AccessDistribution, determinants and normal reference values of aortic arch width: Thoracic aortic geometry in the Framingham Heart Study
- 1 December 2022
- Published by Elsevier in Clinical Imaging
- Vol. 94, 79-84
Prevalence and distribution of aortic plaque by sex and age group among community-dwelling adults
- 1 December 2022
- Published by Elsevier in Clinical Imaging
- Vol. 94, 79-84
Prevalence and distribution of aortic plaque by sex and age group among community-dwelling adults